Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

It is well-known that atrophic gastritis is a major risk factor for gastric cancer, which leads to variations in the serum levels of gastrin, pepsinogen (PG) I, and PGII. We want to assess the effects of age, sex, and Helicobacter pylori status on pepsinogen (PG) level for atrophic gastritis and whether gastric atrophy based on the PG test would be improved after H. pylori eradication.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yonsei University
• Treatments: Gastrins

Criteria

Inclusion Criteria:

1. over 19 years

2. the patients who have gastrointestinal discomfort or get esophagogastroduodenoscopy (EGD) for health check up

3. the patients who got the procedure, endoscopic submucosal resection (ESD) for early gastric cancer

Exclusion Criteria:

1. gastrectomy history

2. advanced gastric cancer (impossible to get the gastrectomy)

3. Helicobacter eradication history

4. the patients who have chronic disease

5. cancer patients except gastric cancer within 6 months

6. who cannot perform this study according to research's decision

7. who have bleeding tendency (ex. taking antiplatelet agent, low platelet count or abnormal coagulation time)